UBS Group AG Purchases 89,591 Shares of InMode Ltd. $INMD

UBS Group AG raised its position in shares of InMode Ltd. (NASDAQ:INMD) by 41.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 308,222 shares of the healthcare company’s stock after purchasing an additional 89,591 shares during the period. UBS Group AG’s holdings in InMode were worth $4,528,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. ARGA Investment Management LP grew its holdings in InMode by 355.0% during the third quarter. ARGA Investment Management LP now owns 143,658 shares of the healthcare company’s stock valued at $2,141,000 after purchasing an additional 112,087 shares during the period. Hussman Strategic Advisors Inc. bought a new position in InMode during the third quarter valued at $1,564,000. State of New Jersey Common Pension Fund D lifted its position in shares of InMode by 612.1% during the third quarter. State of New Jersey Common Pension Fund D now owns 96,120 shares of the healthcare company’s stock worth $1,432,000 after acquiring an additional 82,621 shares in the last quarter. Doma Perpetual Capital Management LLC lifted its position in shares of InMode by 26.8% during the third quarter. Doma Perpetual Capital Management LLC now owns 2,838,431 shares of the healthcare company’s stock worth $42,293,000 after acquiring an additional 599,108 shares in the last quarter. Finally, Ancient Art L.P. purchased a new stake in shares of InMode during the third quarter worth $14,254,000. 68.04% of the stock is owned by institutional investors.

InMode Price Performance

NASDAQ:INMD opened at $13.74 on Friday. The company has a market cap of $870.57 million, a P/E ratio of 10.10 and a beta of 1.97. The stock’s fifty day moving average price is $13.90 and its two-hundred day moving average price is $14.24. InMode Ltd. has a 1 year low of $12.72 and a 1 year high of $16.74.

InMode (NASDAQ:INMD) last posted its earnings results on Wednesday, May 6th. The healthcare company reported $0.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.30 by ($0.05). The company had revenue of $82.02 million for the quarter, compared to analysts’ expectations of $79.84 million. InMode had a return on equity of 13.47% and a net margin of 23.27%.The company’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.31 EPS.

Wall Street Analysts Forecast Growth

INMD has been the topic of several recent research reports. Robert W. Baird dropped their target price on InMode from $17.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. BTIG Research restated a “neutral” rating on shares of InMode in a research report on Monday, January 26th. Finally, Barclays set a $19.00 target price on InMode and gave the stock an “overweight” rating in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, InMode currently has a consensus rating of “Hold” and a consensus price target of $16.00.

InMode Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.